SCHEMBL1368459

SCHEMBL1368459

c1ccc2c(c1)ccc1nnnn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.46
MEN1 O00255 7/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
PBRM1 Q86U86 1/20 0.46
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 8/20 0.41
MAPT P10636 7/20 0.41
TNKS O95271 4/20 0.41
RAB9A P51151 2/20 0.41
HPGD P15428 5/20 0.37
TSHR P16473 2/20 0.37
HSD17B10 Q99714 2/20 0.36
MAPK1 P28482 2/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
CA12 O43570 2/20 0.34
CA9 Q16790 2/20 0.34
BRD4 O60885 1/20 0.34
BRPF1 P55201 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12638572 0.74 MEN1 (0.36) KMT2AMEN1KDM4EMAPTTNKS
SCHEMBL12638571 0.74 MAPT (0.44) KMT2AMEN1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL12638578 0.74 CYP2C9 (0.37) KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL12638535 0.71 ALDH1A1 (0.41) KMT2AMEN1SMN1; SMN2ALDH1A1MAPT
SCHEMBL18472549 0.71 KCNJ1 (0.41) KMT2AMEN1SMN1; SMN2TNKSRAB9A
SCHEMBL5656535 0.69 KMT2A (0.44) KMT2AMEN1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL1602588 0.69 ADORA3 (0.54) KMT2AMEN1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL19782842 0.69 KCNJ1 (0.32) KMT2AMEN1HPGDTSHR
SCHEMBL1368505 0.68 EGLN2 (0.46) SMN1; SMN2L3MBTL1PBRM1ALDH1A1KDM4E
SCHEMBL4508980 0.67 KDM4E (0.35) KMT2AMEN1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3092230-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2018-07-11 EP claimed
US-9718808-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2017-08-01 US claimed
US-20170037037-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2017-02-09 US claimed
EP-3092230-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2016-11-16 EP claimed
WO-2015103756-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2015-07-16 WO claimed
WO-2015105736-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2015-07-16 WO claimed
EP-0745154-B1 MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM LIGNOZYM GMBH (DE) 1998-09-16 EP claimed
EP-0845026-A1 MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES CALL, Hans-Peter Dr. (DE) 1998-06-03 EP claimed
WO-1997048786-A1 MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES CALL HANS PETER (DE) 1997-12-24 WO claimed
EP-0717143-A1 Multicomponents system for modifying decomposing or bleaching of lignin or materials containing it or similar components and the way to use it Lignozym GmbH (DE) 1996-06-19 EP claimed
US-12102631-B2 Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2024-10-01 US disclosed
EP-3863632-B1 QUINOLYLNITRONE FOR USE IN THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA ISQUAEMIA BIOTECH S L (ES) 2023-06-07 EP disclosed
EP-3169672-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2020-04-29 EP disclosed
EP-3169673-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2020-04-29 EP disclosed
US-10208064-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. 2019-02-19 US disclosed
US-3987196-A FUNGISTATS ELI LILLY AND COMPANY (US) 1976-10-19 US disclosed
US-3979387-A PROTECTION OF PLANTS FROM FOLIAR PATHOGENS ELI LILLY AND COMPANY (US) 1976-09-07 US disclosed
US-3974286-A INSECTICIDES ELI LILLY AND COMPANY (US) 1976-08-10 US disclosed
US-3891653-A Substituted 4-5 dehydro-tetrazolo(1,5-a)quinolenes LILLY CO ELI 1975-06-24 US disclosed
US-3764681-A CERTAIN TETRAZOLO-(1,5-A) QUINOLINE COMPOUNDS AS FUNGUS CONTROL AGENTS LILLY CO ELI 1973-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12102631-B2 Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia NLN, TXN2, TXN KMT2A 4346/4885MEN1 2921/4885SMN1; SMN2 65/4885
US-10208064-B2 Inhibitors of the renal outer medullary potassium channel KCNJ11, KCNJ1, KCNJ2 KMT2A 1602/4885MEN1 336/4885SMN1; SMN2 1921/4885
US-20170037037-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 KMT2A 1602/4885MEN1 336/4885SMN1; SMN2 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.